Since previous research reports that the AKT pathway is downstream of EGFR, we hypothesized that PLOD2 might play an oncogenic role in ccRCC via the EGFR/AKT signaling axis. The gene discussed is PLOD2; the disease is nonpapillary renal cell carcinoma.